Caris Life Sciences Inc. (CAI) exhibits 41.0% gross margins and 4.4% return on invested capital within Health Care (Medical Specialities), balanced against a 95.0x enterprise multiple and 6.6% implied options volatility.
Sustained 41.0% gross profitability converts into 5.6% operating margin and 4.4% ROIC, outpacing sector cost of capital.
ROIC: 4.4% // GM: 41.0%YoY revenue trajectory of +97.0% paired with 0.65% free cash flow yield supports self-funded R&D and capital return.
REV YOY: +97.0% // FCF YLD: 0.65%Altman Z-Score of 9.79 and Piotroski F-Score of 8/9 indicate low near-term refinancing stress.
ALTMAN Z: 9.79 // F-SCORE: 8/9Trading at 24.0x trailing P/E (21.0x Fwd P/E) leaves valuation vulnerable if real 10Y TIPS yields spike.
P/E: 24.0x // EV/EBITDA: 95.0xOptions market prices a ±6.6% implied move with a 0.78 put/call ratio around $35.00 max pain.
IMPL MOVE: ±6.6% // P/C: 0.78Elevated industry capital intensity and customer concentration in Medical Specialities require continuous execution to defend -8.4% net margins.
NET MARGIN: -8.4% // D/E: 0.66x| FILER | SIDE | $ VALUE |
|---|---|---|
| INSPECT FULL OWNERSHIP LEDGER IN OWN <GO> | ||
| STRIKE / EXP | TYPE | PREMIUM |
|---|---|---|
| INSPECT GEX & CHAIN IN OPT <GO> | ||
Unblur the exact $50,000 delta-adjusted ETF/options hedge ratio for CAI & activate live FRED threshold breach alerts.